What You Should Know:
– Myriad Genetics, a leader in genetic testing and precision medicine, has announced a collaboration with Flatiron Health, a healthcare technology company focused on oncology solutions, to integrate Myriad’s MyRisk® Hereditary Cancer Test into Flatiron’s OncoEMR® platform.
– This integration will streamline the process of ordering and reviewing genetic testing results for clinicians within Flatiron’s network of community-based cancer care providers.
Improving Access to Genetic Testing
This partnership aims to improve access to genetic testing and enhance personalized cancer care by making it easier for clinicians to incorporate MyRisk into their workflows. With this integration, over 4,200 providers at more than 800 cancer care locations across the U.S. can now order, receive, and review MyRisk test results directly within their OncoEMR system.
MyRisk Hereditary Cancer Test
Myriad’s MyRisk test is a comprehensive genetic test that assesses an individual’s risk for hereditary cancers. It analyzes multiple genes associated with an increased risk of developing various types of cancer, including breast, ovarian, colon, and prostate cancer.
OncoEMR: A Cloud-Based EMR for Cancer Care
Flatiron Health’s OncoEMR is a cloud-based electronic medical record platform specifically designed for oncology practices. It provides a comprehensive suite of tools for managing patient care, including scheduling, charting, billing, and reporting.
